TOPICAL THERAPY FOR GENITAL HERPES

氧化还原制药公司的新的抗病毒和抗炎 有机金属化合物CTC 96（DoxovirTM）已证实具有活性 在细胞培养物和动物中抗单纯疱疹病毒（HSV）1型 人类眼部疾病的模型。 与HSV-2密切相关， 生殖器疱疹的危害有哪些？生殖器疱疹的危害有哪些？ 在动物模型中研究。 在初步实验中，局部治疗 CTC 96导致原发性疾病的发病率降低， 生殖道中的病毒，伴随着随后的减少， 自发复发 治疗后的这种长期效果 原发性疾病是目前可用的抗病毒药物所无法比拟的。 为了验证这些效果，并探讨治疗的位点， 活性，建立豚鼠生殖器疱疹和小鼠模型 将使用热再活化。 最佳CTC 96浓度范围 将定义治疗和预防，以及CTC 96对 潜伏期建立和再活化潜伏病毒的复制将 被确定。 Redox打算寻求IND批准，用于测试 局部CTC 96在人类生殖器疱疹临床试验中作为目标 第二阶段SBIR应用。 拟议的商业应用：这项研究将阐明 Redox抗疱疹剂（CTC 96; DoxovirTM）在治疗中的用途， 预防原发性生殖器疱疹和复发性感染。 有 美国每年约有70万例原发病例和2000万例复发病例 一个人 全球主要抗疱疹药物的年销售额， 阿昔洛韦，超过10亿美元。 DoxovirTM也可以用于 口面疱疹（每年约50，000，000例）和其他皮肤疱疹 感染（例如，带状疱疹）。 潜在市场包括传染病 专家、皮肤科医生和全科医生， 患者

Redox Pharmaceutical Corporation's new antiviral and anti-inflammatory organometallic compound, CTC 96 (DoxovirTM) has demonstrated activity against herpes simplex virus (HSV) type-1 in cell culture and animal models of human ocular disease. The closely related HSV-2), which is the cause of millions and cases of genital herpes each year in the US, will be studied in animal models. In preliminary experiments, topical therapy with CTC 96 resulted in a reduced incidence of primary disease and reduced virus in the genital tract, accompanied by a reduction of subsequent spontaneous recurrence. This long-lasting effect following treatment of primary disease is unparalleled with currently available antiviral drugs. To verify these effects and to investigate the locus of therapeutic activity, established models of guinea pig genital herpes and mouse thermal reactivation will be used. Optimal CTC 96 concentration ranges for therapy and prophylaxis will be defined, and CTC 96 influence on the establishment of latency and replication of reactivated latent virus will be determined. Redox intends to pursue IND approval for testing of topical CTC 96 in human clinical trials of genital herpes as an objective of a Phase II SBIR application. PROPOSED COMMERCIAL APPLICATION: This research will clarify the potential use of Redox's antiherpetic agent (CTC 96; DoxovirTM) for therapy and prevention of primary genital herpes and recurrent infections. There are about 700,000 primary cases and 20 million recurrences annually in the US alone. Yearly worldwide sales of th leading antitherpetic drug, acyclovir, exceed $1 billion. DoxovirTM could also be useful for orofacial herpes (about 50,000,000 cases per year) and other dermal herpes infections (e.g., shingles). Potential markets include infectious disease specialists, dermatologists and general practitioners world-wide and their patients.